Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07192900 · ClinicalTrials.gov registry record · Phase 1
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
A Phase 1 study of Malignant Mesothelioma and Malignant Pleural Effusion, sponsored by David Bartlett, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07192900 is a Phase 1 study of Malignant Mesothelioma and Malignant Pleural Effusion that is actively recruiting participants, run by David Bartlett, MD. The registered enrollment target is 10 participants, below the 75-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07192900, a Phase 1 study of Malignant Mesothelioma and Malignant Pleural Effusion, is actively recruiting participants, sponsored by David Bartlett, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltrating T-cells (PIT). It is administered through a pleural catheter along with the drug Interleukin-2 (IL-2). Based on previous research it is believed that it may help fight the tumor and relieve symptoms. As a participant, their pleural fluid will be collected and the PIT cells will be isolated and expanded in the lab to create the ACT product. Before receiving the ACT product through their pleural catheter, they will undergo outpatient lymphodepleting chemotherapy. LDC is a standard procedure for many approved immunotherapy treatments Following the infusion, they'll receive IL-2 through the catheter for two days to stimulate the expanded PIT cells. The active treatment phase lasts about three weeks, with follow-up visits over five years at AHN West Penn Hospital, potentially requiring a hospital stay of up to six days. Blood samples will be taken to monitor their response. As this is a first-in-human study, treatment carries an unknown risk up to and including death from toxicity. However, the risks of similar immunotherapy treatments are well documented.
Conditions Studied
Interventions
- DRUG Interleukin-2
- BIOLOGICAL locally manufactured adoptive cellular therapy (ACT) product
Study Locations (1)
Pennsylvania
- AHN West Penn Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-03 |
| Est. Completion | 2037-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07192900
The ClinicalTrials.gov registry entry for NCT07192900 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 75-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (87% lower). The listed sponsor is David Bartlett, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Interleukin-2 is the first listed.
NCT07192900 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07192900 about?
NCT07192900 is a clinical study titled "Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease". This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltratin...
What is the current status of trial NCT07192900?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2026-03. Estimated completion is 2037-12.
What conditions does trial NCT07192900 study?
This clinical trial studies the following conditions: Malignant Mesothelioma, Malignant Pleural Effusion, Pleural Effusion, Malignant, Metastasis to Pleura.
What interventions are being tested in trial NCT07192900?
The interventions under investigation include: Interleukin-2 (DRUG), locally manufactured adoptive cellular therapy (ACT) product (BIOLOGICAL).
Who is sponsoring clinical trial NCT07192900?
This trial is sponsored by David Bartlett, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07192900 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
RECRUITING · Phase 1
-
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
COMPLETED · Phase 1
-
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
COMPLETED · Phase 1
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.